Compare Charles River Laboratories Intl. Inc (CRL) vs Figs Inc (FIGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Figs Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while Figs Inc trades at $9.79 (market cap $1.62B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 6.9× Figs Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Figs Inc nearer its low. Which is the better fit depends on your goals.
| CRL | FIGS | |
|---|---|---|
Market Cap | $11.14B | $1.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $233.60 | $17.12 |
52-Week Low | $145.57 | $5.81 |
Enterprise Value | $14.00B | $1.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
FIGS trades at $10.00, down 0.4% on the day, with a bearish technical signal from moving averages but recent earnings beats. The company reported Q1 2026 revenue growth of 28% and raised full-year guidance, though net cash flow remains negative. Analyst consensus is a Buy with a $19.50 price target, implying significant upside from current levels.
The outlook is mixed: strong fundamentals and growth prospects support the bull case, but valuation is rich at a P/E of 45.45, and margin pressures from tariffs and spending pose risks. The stock's performance hinges on execution of global expansion and cost management amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →
